Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Caveolin-1: a marker for pancreatic cancer diagnosis.

Tanase CP.

Expert Rev Mol Diagn. 2008 Jul;8(4):395-404. doi: 10.1586/14737159.8.4.395. Review.

PMID:
18598222
2.

Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.

Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME.

J Mol Histol. 2009 Feb;40(1):23-9. doi: 10.1007/s10735-008-9209-7. Epub 2009 Jan 22.

PMID:
19160064
3.

Molecular markers of early pancreatic cancer.

Goggins M.

J Clin Oncol. 2005 Jul 10;23(20):4524-31. Review.

PMID:
16002843
4.
5.

Molecular prognostic factors in patients with pancreatic cancer.

Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D.

Expert Opin Ther Targets. 2007 Dec;11(12):1553-69. Review.

PMID:
18020978
6.

Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.

Dittert DD, Kielisch C, Alldinger I, Zietz C, Meyer W, Dobrowolski F, Saeger HD, Baretton GB.

Hum Pathol. 2008 Jul;39(7):1002-10. doi: 10.1016/j.humpath.2007.11.016. Epub 2008 May 20.

PMID:
18495213
7.

Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma.

Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52. doi: 10.1158/1055-9965.EPI-07-2791.

8.

Midkine mRNA is overexpressed in pancreatic cancer.

Ohhashi S, Ohuchida K, Mizumoto K, Egami T, Yu J, Cui L, Toma H, Takahata S, Nabae T, Tanaka M.

Dig Dis Sci. 2009 Apr;54(4):811-5. doi: 10.1007/s10620-008-0434-4. Epub 2008 Aug 21.

PMID:
18712601
9.

Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H.

Clin Cancer Res. 2008 Nov 1;14(21):7043-9. doi: 10.1158/1078-0432.CCR-08-0381.

10.

Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.

Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL, Andruss BF.

Expert Rev Mol Diagn. 2011 Apr;11(3):249-57. doi: 10.1586/erm.11.10.

PMID:
21463235
11.

Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.

Singh P, Srinivasan R, Wig JD.

Pancreas. 2011 Jul;40(5):644-52. doi: 10.1097/MPA.0b013e31821ff741. Review.

PMID:
21673535
12.

Prognostic markers in pancreatic ductal adenocarcinomas.

Hezel AF, Bardeesy N.

Cancer Biol Ther. 2008 Sep;7(9):1360-1. Epub 2008 Sep 6. No abstract available.

PMID:
18836287
13.

Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.

Ansari D, Rosendahl A, Elebro J, Andersson R.

Br J Surg. 2011 Aug;98(8):1041-55. doi: 10.1002/bjs.7574. Epub 2011 Jun 6. Review.

PMID:
21644238
14.

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH.

Clin Cancer Res. 2007 Dec 15;13(24):7380-7.

15.

Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.

La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E.

Hum Pathol. 2009 Jan;40(1):30-40. doi: 10.1016/j.humpath.2008.06.005. Epub 2008 Aug 20.

PMID:
18715612
16.

Detecting and diagnosing ampullary neoplasms.

Wang LF, Hingorani SR, Tuveson DA.

Cancer Biol Ther. 2004 Jul;3(7):657-9. Epub 2004 Jul 20. No abstract available.

PMID:
15326385
17.

Alterations of cell signaling pathways in pancreatic cancer.

Freeman JW, DeArmond D, Lake M, Huang W, Venkatasubbarao K, Zhao S.

Front Biosci. 2004 May 1;9:1889-98. Review.

PMID:
14977595
18.

Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.

Fong ZV, Winter JM.

Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea. Review.

PMID:
23187839
19.

Pancreatic cancer: a plea for good and comprehensive morphological studies.

Alg├╝l H, Schmid RM.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):713-5. doi: 10.1097/MEG.0b013e3282f9460e. Review.

PMID:
18617774
20.

Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma.

Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C.

Surg Oncol. 2012 Dec;21(4):e171-82. doi: 10.1016/j.suronc.2012.07.004. Epub 2012 Sep 12. Review.

PMID:
22981281

Supplemental Content

Support Center